Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

Maximilian J Hochmair1 Department of Respiratory & Critical Care Medicine,Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord,3500Vienna,AustriaCorrespondence[email protected]

https://orcid.org/0000-0002-8673-2450 View further author information

Alessandro Morabito2 Thoracic Medical Oncology,Istituto Nazionale Tumori, “Fondazione G. Pascale”-IRCCS, 80131Napoli,Italy

https://orcid.org/0000-0002-1319-9608 View further author information

Desiree Hao3 Tom Baker Cancer Center,Cummings School of Medicine,University of Calgary, Calgary,ABT2N 4N1,CanadaView further author information

Cheng-Ta Yang4 Department of Thoracic Medicine,Chang Gung Memorial Hospital, 333Taoyuan,TaiwanView further author information

Ross A Soo5 Department of Haematology-Oncology,National University Hospital, SingaporeView further author information

James C-H Yang6 Department of Oncology,National Taiwan University Hospital & National Taiwan University Cancer Center, Taipei,TaiwanView further author information

Rasim Gucalp7 Department of Oncology,Montefiore/Albert Einstein Cancer Center, Bronx,NY10461,USAView further author information

Balazs Halmos7 Department of Oncology,Montefiore/Albert Einstein Cancer Center, Bronx,NY10461,USAView further author information

Angela Märten8 Boehringer Ingelheim International GmbH, 55216Ingelheim am Rhein,GermanyView further author information

Tanja Cufer9 University Clinic Golnik,University of Ljubljana, 4204 Ljubljana,SloveniaView further author information

show all

Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

Supplementary Figure 1

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

Supplementary Figure 1

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date